AstraZeneca has joined the ranks of big pharma companies bolting on RNA-based technology platforms in the wake of the stellar success of mRNA vaccines for COVID-19.
Japan’s Taisho Pharmaceutical looks like it could be heading into private ownership, thanks to a management buyout offer (MBO) that could value the company at almost $5 bi
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio